URGN
HEALTHCAREUroGen Pharma Ltd
Live · NASDAQ · May 9, Close
What's Moving URGN Today?
No stock-specific AI insight has been generated for URGN yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$26.25
Fundamentals
Trading
URGN News
20 articles- Assessing UroGen Pharma (URGN) Valuation After Q1 2026 Earnings Beat And Zusduri Launch MomentumYahoo Finance·May 9, 2026
- UroGen (URGN) Q1 2026 Earnings TranscriptMotley Fool·May 7, 2026
- UroGen Pharma Ltd. Q1 2026 Earnings Call SummaryMoby·May 7, 2026
- UroGen Pharma to Present at Upcoming Investor ConferencesYahoo Finance·May 7, 2026
- Urogen Pharma Q1 Earnings Call HighlightsMarketbeat·May 7, 2026
- Urogen Pharma (URGN) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 6, 2026
- UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and HighlightsYahoo Finance·May 6, 2026
- Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 5, 2026
- UroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026Yahoo Finance·Apr 29, 2026
- UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial CancerYahoo Finance·Apr 8, 2026
- Why The UroGen Pharma (URGN) Investment Story Is Shifting As Analysts Hold Fair Value SteadyYahoo Finance·Apr 4, 2026
- Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURIYahoo Finance·Mar 30, 2026
- As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors?Motley Fool·Mar 23, 2026
- How UroGen Pharma (URGN) Narrative Is Evolving Around Fair Value Risks And OpportunitiesYahoo Finance·Mar 20, 2026
- Sionna Stock Is Up 144% This Past Year. Is the Biotech a Buy as One Fund Makes a $7 Million Bet?Motley Fool·Mar 18, 2026
- This $6 Million Bet Adds a Brain Health Biotech to Portfolio Dominated by Clinical Stage NamesMotley Fool·Mar 18, 2026
- This Biotech Fund Sold $8 Million of Terns Stock Last Quarter, but Here's Why It Still Seems Very BullishMotley Fool·Mar 18, 2026
- UroGen Applauds BCAN’s New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of RecurrenceYahoo Finance·Mar 13, 2026
- UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Mar 6, 2026
- UroGen Weighs ENVISION Success And Expanded Loan In Bladder Cancer PushYahoo Finance·Mar 5, 2026
All 20 articles loaded
Price Data
52-Week Range
$26.25
Fundamentals
Trading
About UroGen Pharma Ltd
UroGen Pharma Ltd (URGN) is an innovative biotechnology company specializing in the development of specialized therapies for urological diseases, with a focus on urothelial carcinoma and bladder cancer. Leveraging its proprietary reverse thermal gel platform, UroGen enables targeted, sustained local drug delivery, thereby optimizing therapeutic efficacy while reducing systemic side effects. With a promising clinical pipeline addressing significant unmet medical needs in urology, UroGen is strategically poised to advance patient care and establish itself as a leader in the urological oncology space.